S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
NASDAQ:JAGX

Jaguar Health - JAGX Stock Forecast, Price & News

$0.16
0.00 (0.00%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.16
$0.17
50-Day Range
$0.16
$0.33
52-Week Range
$0.15
$2.66
Volume
2.85 million shs
Average Volume
3.42 million shs
Market Capitalization
$18.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Jaguar Health MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
10.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.17mentions of Jaguar Health in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.67) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

1019th out of 1,095 stocks

Pharmaceutical Preparations Industry

503rd out of 547 stocks

JAGX stock logo

About Jaguar Health (NASDAQ:JAGX) Stock

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Stock News Headlines

Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com
Short Volatility Alert: Jaguar Health, Inc.
See More Headlines
Receive JAGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter.

JAGX Company Calendar

Last Earnings
8/22/2022
Today
10/02/2022
Next Earnings (Estimated)
11/16/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JAGX
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

Net Income
$-52,600,000.00
Net Margins
-652.35%
Pretax Margin
-654.84%

Debt

Sales & Book Value

Annual Sales
$4.34 million
Book Value
$0.23 per share

Miscellaneous

Free Float
118,501,000
Market Cap
$18.73 million
Optionable
Not Optionable
Beta
1.65

Key Executives

  • Ms. Lisa A. Conte (Age 63)
    Founder, CEO, Pres & Director
    Comp: $722.54k
  • Mr. Jonathan S. Wolin CPA (Age 60)
    J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Counsel
    Comp: $478.72k
  • Mr. Ian H. Wendt M.B.A. (Age 54)
    Chief Commercial Officer
    Comp: $431.55k
  • Dr. Steven R. King Ph.D. (Age 64)
    Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
    Comp: $452.61k
  • Ms. Carol R. Lizak (Age 58)
    Chief Financial Officer
  • Dr. Pravin R. Chaturvedi Ph.D. (Age 59)
    Chief Scientific Officer & Chair of Scientific Advisory Board
  • Mr. Peter Hodge
    Sr. Director of Investor Relations, Bus. Devel. & Special Events
  • Dr. Karen J. Brunke Ph.D.
    Exec. VP of Corp. & Bus. Devel.
  • Mr. David Sesin
    Chief Manufacturing Officer
  • Dr. Michael K. Guy D.V.M.
    M.S., Ph.D., VP of Preclinical & Nonclinical Studies













JAGX Stock - Frequently Asked Questions

How have JAGX shares performed in 2022?

Jaguar Health's stock was trading at $1.04 on January 1st, 2022. Since then, JAGX stock has decreased by 85.0% and is now trading at $0.1560.
View the best growth stocks for 2022 here
.

When is Jaguar Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 16th 2022.
View our JAGX earnings forecast
.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) posted its earnings results on Monday, August, 22nd. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. The biotechnology company had revenue of $2.92 million for the quarter. Jaguar Health had a negative net margin of 652.35% and a negative trailing twelve-month return on equity of 486.62%.

When did Jaguar Health's stock split?

Jaguar Health's stock reverse split before market open on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $0.16.

How much money does Jaguar Health make?

Jaguar Health (NASDAQ:JAGX) has a market capitalization of $18.73 million and generates $4.34 million in revenue each year. The biotechnology company earns $-52,600,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The official website for the company is www.jaguaranimalhealth.com. The biotechnology company can be reached via phone at (415) 371-8300.

This page (NASDAQ:JAGX) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.